The place of VEGF inhibition in the current management of renal cell carcinoma

British Journal of Cancer
P NathanT Eisen

Abstract

Vascular endothelial growth factor (VEGF) is overexpressed in around 80% of patients with clear cell carcinoma of the kidney owing to the inactivation of von Hippel Lindau gene activity. VEGF stimulates angiogenesis and acts as an autocrine growth factor. A number of different agents are now available which target VEGF and its signalling pathways. A significant body of evidence has accumulated demonstrating that antagonism of VEGF and its downstream pathways is clinically useful in a significant proportion of patients with metastatic clear cell carcinoma of the kidney. Enough data is now available to recommend that patients with metastatic clear cell carcinoma of the kidney should at some point during the course of their disease be offered entry into a clinical trial enabling exposure to a targeted inhibitor of VEGF or its signalling pathways. Assuming early clinical trial data is substantiated by ongoing registration studies, efforts should be made to minimise the time taken between licensing and general availability of these active agents.

References

May 1, 1994·Nature Genetics·J R GnarraF M Duh
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Sep 18, 2003·Nature Reviews. Cancer·Gregg L Semenza
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nancy A DawsonArif Hussain
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottMichael B Atkins
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey W ClarkHeinz-Josef Lenz
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthAnthony Greco

❮ Previous
Next ❯

Citations

Feb 28, 2008·Physiological Genomics·Liliana Moreno-VinascoJoe G N Garcia
Dec 15, 2010·Proceedings of the National Academy of Sciences of the United States of America·Venkata R DoppalapudiRodney W Lappe
Apr 11, 2008·BJU International·Erik G HavranekHardev Pandha
Jul 11, 2007·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jyoti D ChouhanJodi L Grabinski
Jul 17, 2021·Current Oncology Reports·Alex ChambersJiaxin Niu
Mar 14, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D B CornelioG Schwartsmann

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Current Cancer Drug Targets
Daniel Y C Heng, Ronald M Bukowski
Annals of Oncology : Official Journal of the European Society for Medical Oncology
M LosE E Voest
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
W Marston LinehanLen Neckers
© 2021 Meta ULC. All rights reserved